Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag FluoGuide raised SEK 104M in a share sale to fund cancer trial development and executive incentives.

flag FluoGuide A/S raised SEK 104 million in a directed share issue on November 3, 2025, issuing 2.7 million shares at SEK 38 each, 95% of the closing price, to Nordic institutional investors including major shareholders. flag The proceeds will fund phase II trials for FG001 in glioma and head and neck cancer, CMC work for a phase III trial, and general operations. flag The company also granted 199,000 warrants to executives and board members at SEK 38, with a three-year vesting period and exercise rights until 2035, aiming to align long-term incentives. flag Shares will list on Nasdaq First North Growth Market by November 14. flag The capital increase raises share capital and results in a 16.69% dilution. flag A 90-day lock-up on new issuances and 180-day sales ban for executives support investor confidence. flag The credit facility remains at SEK 40 million, extended to April 2027.

4 Articles